NASDAQ · TRIB
Trinity Biotech plc
$6.63-$0.17 (-2.5%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.37% below the high.
Loading market information…
NASDAQ · BFRI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Biofrontera Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.22. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Biofrontera Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | -$0.47-118.6% vs estimate | $8.59M-18.6% vs estimate |
|---|
| Q4 2024 | Mar 21, 2025 | -$0.19-1,050.0% vs estimate | $12.56M-13.68% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.98-18.07% vs estimate | $9.01M-9.88% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$6.63-$0.17 (-2.5%)
Trinity Biotech plc’s quoted price sits in the lower half of its reported 52-week range, 87.37% below the high.
$1.23-$0.01 (-0.81%)
Dogwood Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.54% below the high.
$1.98+$0.01 (+0.51%)
Aytu BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.5% below the high.
$0.98-$0.01 (-1.01%)
Cocrystal Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.3% below the high.
$13.85-$3.97 (-22.28%)
Sensei Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.32% below the high.
$3.33+$0.22 (+7.07%)
Sunshine Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.28% below the high.
$0.83+$0.00 (+0.35%)
Imunon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.61% below the high.
$0.51+$0.02 (+5.11%)
Gelteq Limited Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 74.83% below the high.
